TMCnet News
Global Biosimilar Pipeline and Market Prospects, 2022: Addressing Production Complexities Through Risk Management and Quality by Design - Research and MarketsResearch and Markets has announced the addition of the "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design" report to their offering. "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through Risk Management and Quality by Design" provides an in-depth assessment of the current trends in the global biosimilars market, with a particular focus on manufacturing complexities and the strategies being implemented to overcome them. Furthermore, it also positions current biosimilar regulatory frameworks and guidelines implemented in the US, Europe, Japan and China, recent updates regarding the key issue of interchangeability, and case studies of successful biosimilar approvals in recent years. Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. A biosimilar is a bio-therapeutic that is clinically highly similar to an approved innovative product (reference product) in terms of active ingredients, and has no meaningful difference in efficacy and safety. The complexities of manufacturing a biological drug also apply to biosimilars. The complex requirements are manifold and have been a significant barrier to the further expansion of the biosimilars market. One of the key challenges biosimilar manufacturers face is the knowledge gap under which these products are developed. This challenge arises from the fact that the innovator product information remains proprietary and must adopt a reverse engineering process. They also need to adopt the latest technology and quality initiatives, such as QbD, DoE and PAT techniques. Organizations also need to adopt a proactive approach in risk mitigation through risk-management-plans (RMP) and long-term studies and through being cognizant of adverse events and adopting production best practices outlined by industry associations and regulatory agencies. A number of biologics will go off patent before 2020, which presents a huge opportunity for biosimilar manufacturers. Pricing discounts for these products usually fall by 30-50% compared with the innovator product. The cost advantages will lead to greater access to these drugs, and significantly reduce the cost of healthcare in many countries. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Key Drivers of Growth in the Global Biosimilars Market 4. Key Barriers to Growth in the Global Biosimilars Market 5. Biosimilar Regulatory Frameworks in Key Geographies 6. Biosimilar Manufacturing Process 7. Key Production Issues and Challenges 8. Approaches to Addressing Biosimilar Manufacturing Complexity 9. Commercial Strategies for Biosimilars Adopted by Big Pharma 10. Global Biosimilar Pipeline Analysis 2017 11. Global Biosimilar Market 2017-2022 12. Future Outlook 13. Conclusion For more information about this report visit http://www.researchandmarkets.com/research/59v8dm/global_biosimilar
View source version on businesswire.com: http://www.businesswire.com/news/home/20170426005563/en/ |
